The Emerging Clinical Application of m6A RNA Modification in Inflammatory Bowel Disease and Its Associated Colorectal Cancer.
The Emerging Clinical Application of m6A RNA Modification in Inflammatory Bowel Disease and Its Associated Colorectal Cancer.
复制标题
DOI：
10.2147/jir.s320449
复制
发表时间：
2021
影响因子：
4.5
通讯作者：
Mao F
中科院分区：
文献类型：
--
作者：
Xu X;Huang J;Ocansey DKW;Xia Y;Zhao Z;Xu Z;Yan Y;Zhang X;Mao F
甲基化，首先在DNA中提出，但后来在RNA中发现，是真核生物中最广泛的表观遗传修饰之一，其中N6-甲基腺苷（m6 A）修饰已被发现在包括结直肠癌（CRC）在内的多种癌症中发挥重要作用。在各种酶和蛋白质的作用下，m6 A在RNA和免疫细胞中的调节作用也逐渐实现。本文综述了m6 A的一般生物学起源和作用，以及m6 A通过调节RNA和免疫细胞在肠粘膜免疫中的重要作用，从而与炎症性肠病（inflammatory bowel disease，IBD）和结直肠癌的发生发展密切相关。m6 A相关基因和调控因子有望成为潜在的预测标志物和治疗靶点。
Methylation, first proposed in DNAs, but later found in RNAs, serves as one of the most widespread epigenetic modifications in eukaryotes, where N6-methyladenosine (m6A) modification has been found to play an important role in a variety of cancers including colorectal cancer (CRC). Under the action of various enzymes and proteins, the regulatory role of m6A in RNAs and immune cells has also been gradually realized. This paper reviews the general biogenesis and effects of m6A, and its emerging crucial role in intestinal mucosal immunity via the regulation of RNAs and immune cells, and thus closely related to the occurrence and development of inflammatory bowel disease (IBD) and CRC. m6A-related genes and regulatory factors are expected to be potential predictive markers and therapeutic targets.